Medical Crossfire: Establishing the Role of Predictive Biomarkers and Testing Strategies for Breast Cancer Management
WebcastFaculty
OVERVIEW
Medical Crossfire: Establishing the Role of Predictive Biomarkers and Testing Strategies for Breast Cancer Management is organized by Physicians Education Resource, LLC (PER) and will be held during Aug 31, 2017 - Aug 31, 2018.
The target audience for this medical event is directed toward medical oncologists, gynecologic oncologists, and fellows who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Overview :
With improved understanding of genotypic and phenotypic methods to characterize breast cancer, clinicians have an ever-increasing ability to personalize care and individualize treatment strategies. There are several biomarkers that have been established as essential to guide the treatment of patients with breast cancer, including the estrogen and progesterone hormonal receptors, as well as HER2. In addition, BRCA mutations assist decision making concerning the potential application of PARP inhibitors for these patients. Clinical trials have also identified other biomarkers of interest, and the search for further prognostic markers and driver mutations is ongoing. It is critical for clinicians to maintain their knowledge and competence concerning the use of biomarkers and tumor testing strategies to optimize outcomes for their patients with these tumors. This Medical Crossfire® activity has been developed to provide clinicians with updates on the latest information regarding biomarkers that may shape treatment selection for their patients. Our panel of experts will discuss and debate key topics, using a balance of didactic presentation and informative interactive discussion.
Learning Objectives :
At the conclusion of this activity, you should be better prepared to:
• Evaluate current and evolving biomarkers, as well as testing methods by which these can be identified, in the setting of breast cancer
• Examine clinical trials that have utilized biomarkers and molecular approaches in patients with breast cancer
• Apply evidence concerning prognostic and predictive markers to inform treatment decisions in multiple lines of care for patients with breast cancer
Additional details will be posted as soon as they are available.
The target audience for this medical event is directed toward medical oncologists, gynecologic oncologists, and fellows who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Overview :
With improved understanding of genotypic and phenotypic methods to characterize breast cancer, clinicians have an ever-increasing ability to personalize care and individualize treatment strategies. There are several biomarkers that have been established as essential to guide the treatment of patients with breast cancer, including the estrogen and progesterone hormonal receptors, as well as HER2. In addition, BRCA mutations assist decision making concerning the potential application of PARP inhibitors for these patients. Clinical trials have also identified other biomarkers of interest, and the search for further prognostic markers and driver mutations is ongoing. It is critical for clinicians to maintain their knowledge and competence concerning the use of biomarkers and tumor testing strategies to optimize outcomes for their patients with these tumors. This Medical Crossfire® activity has been developed to provide clinicians with updates on the latest information regarding biomarkers that may shape treatment selection for their patients. Our panel of experts will discuss and debate key topics, using a balance of didactic presentation and informative interactive discussion.
Learning Objectives :
At the conclusion of this activity, you should be better prepared to:
• Evaluate current and evolving biomarkers, as well as testing methods by which these can be identified, in the setting of breast cancer
• Examine clinical trials that have utilized biomarkers and molecular approaches in patients with breast cancer
• Apply evidence concerning prognostic and predictive markers to inform treatment decisions in multiple lines of care for patients with breast cancer
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links